Browse GFAP

Summary
SymbolGFAP
Nameglial fibrillary acidic protein
Aliases FLJ45472; ALXDRD
Chromosomal Location17q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Note=Associated with intermediate filaments.
Domain PF00038 Intermediate filament protein
PF04732 Intermediate filament head (DNA binding) region
Function

GFAP, a class-III intermediate filament, is a cell-specific marker that, during the development of the central nervous system, distinguishes astrocytes from other glial cells.

> Gene Ontology
 
Biological Process GO:0001504 neurotransmitter uptake
GO:0001505 regulation of neurotransmitter levels
GO:0006836 neurotransmitter transport
GO:0006914 autophagy
GO:0010001 glial cell differentiation
GO:0010506 regulation of autophagy
GO:0010624 regulation of Schwann cell proliferation
GO:0010625 positive regulation of Schwann cell proliferation
GO:0010720 positive regulation of cell development
GO:0010721 negative regulation of cell development
GO:0010975 regulation of neuron projection development
GO:0010977 negative regulation of neuron projection development
GO:0014002 astrocyte development
GO:0014009 glial cell proliferation
GO:0014010 Schwann cell proliferation
GO:0014013 regulation of gliogenesis
GO:0014015 positive regulation of gliogenesis
GO:0021782 glial cell development
GO:0030198 extracellular matrix organization
GO:0031099 regeneration
GO:0031102 neuron projection regeneration
GO:0031345 negative regulation of cell projection organization
GO:0042063 gliogenesis
GO:0043062 extracellular structure organization
GO:0043254 regulation of protein complex assembly
GO:0045103 intermediate filament-based process
GO:0045104 intermediate filament cytoskeleton organization
GO:0045109 intermediate filament organization
GO:0045665 negative regulation of neuron differentiation
GO:0048167 regulation of synaptic plasticity
GO:0048708 astrocyte differentiation
GO:0050768 negative regulation of neurogenesis
GO:0050769 positive regulation of neurogenesis
GO:0050804 modulation of synaptic transmission
GO:0050806 positive regulation of synaptic transmission
GO:0051580 regulation of neurotransmitter uptake
GO:0051588 regulation of neurotransmitter transport
GO:0051961 negative regulation of nervous system development
GO:0051962 positive regulation of nervous system development
GO:0060020 Bergmann glial cell differentiation
GO:0060251 regulation of glial cell proliferation
GO:0060252 positive regulation of glial cell proliferation
GO:0060291 long-term synaptic potentiation
GO:0061684 chaperone-mediated autophagy
GO:0098657 import into cell
GO:1904714 regulation of chaperone-mediated autophagy
Molecular Function GO:0001948 glycoprotein binding
GO:0005178 integrin binding
GO:0005200 structural constituent of cytoskeleton
GO:0050839 cell adhesion molecule binding
Cellular Component GO:0005765 lysosomal membrane
GO:0005882 intermediate filament
GO:0043209 myelin sheath
GO:0044297 cell body
GO:0045111 intermediate filament cytoskeleton
GO:0097386 glial cell projection
GO:0097449 astrocyte projection
GO:0097450 astrocyte end-foot
GO:0098552 side of membrane
GO:0098562 cytoplasmic side of membrane
GO:0098574 cytoplasmic side of lysosomal membrane
GO:0098852 lytic vacuole membrane
> KEGG and Reactome Pathway
 
KEGG hsa04630 Jak-STAT signaling pathway
Reactome R-HSA-1251985: Nuclear signaling by ERBB4
R-HSA-162582: Signal Transduction
R-HSA-1236394: Signaling by ERBB4
Summary
SymbolGFAP
Nameglial fibrillary acidic protein
Aliases FLJ45472; ALXDRD
Chromosomal Location17q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between GFAP and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between GFAP and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
27618707Gastroesophageal Junction Adenocarcinoma; Prostate Adenocarcinoma; Plasma Cell Myeloma; Melanoma; Colon Neuroendocrine Tumor G1; Parotid Gland Pleomorphic Adenoma; TeratomaPromote immunity (T cell function)Neoplasia was diagnosed within 3 years of neurologic onset in 6 of 16 patients (38%): prostate and gastroesophageal adenocarcinomas, myeloma, melanoma, colonic carcinoid, parotid pleomorphic adenoma, and teratoma. Expression of GFAP has been reported in some of the tumor types identified in paraneoplastic cases. Glial fibrillary acidic protein peptide-specific cytotoxic CD8+ T cells are implicated as effectors in a transgenic mouse model of autoimmune GFAP meningoencephalitis.
Summary
SymbolGFAP
Nameglial fibrillary acidic protein
Aliases FLJ45472; ALXDRD
Chromosomal Location17q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of GFAP in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolGFAP
Nameglial fibrillary acidic protein
Aliases FLJ45472; ALXDRD
Chromosomal Location17q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of GFAP in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0440.902
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0310.971
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.1330.899
729033130MelanomaallAnti-PD-1 (nivolumab) 262301
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 151101
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 111201
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 482.0290.039
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.9440.163
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0060.981
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of GFAP in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.509.50.492
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.4015.40.482
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91622.26.2160.53
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 382707.4-7.40.169
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 2213015.4-15.40.131
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolGFAP
Nameglial fibrillary acidic protein
Aliases FLJ45472; ALXDRD
Chromosomal Location17q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of GFAP. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolGFAP
Nameglial fibrillary acidic protein
Aliases FLJ45472; ALXDRD
Chromosomal Location17q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of GFAP. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by GFAP.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolGFAP
Nameglial fibrillary acidic protein
Aliases FLJ45472; ALXDRD
Chromosomal Location17q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of GFAP. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolGFAP
Nameglial fibrillary acidic protein
Aliases FLJ45472; ALXDRD
Chromosomal Location17q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of GFAP expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolGFAP
Nameglial fibrillary acidic protein
Aliases FLJ45472; ALXDRD
Chromosomal Location17q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between GFAP and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolGFAP
Nameglial fibrillary acidic protein
Aliases FLJ45472; ALXDRD
Chromosomal Location17q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting GFAP collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.